课题基金 / 基金详情

GENE THERAPY FOR LONG-TERM MYOCARDIAL PROTECTION

GENE THERAPY FOR LONG-TERM MYOCARDIAL PROTECTION
长期心肌保护的基因治疗
批准号:
6866423
负责人:
Victor J Dzau
金额:
$49.01万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-05-02 至 2007-03-31

项目摘要

项目成果

Victor J Dzau的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): In this application we propose to develop a preventive gene therapy strategy for myocardium protection from future ischemia/reperfusion injury (I/R) involving a single administration of a therapeutic gene with a vector system capable of efficient and long term myocyte specific and inducible expression of the therapeutic gene. We will employ recombinant adeno-associated viral vectors (rAAV) to achieve long-term and stable expression of transduced genes in the myocardium. We will select cis-acting promoter elements that are capable of conferring inducible and cell-specific gene expression and to use these elements as molecular switches to achieve optimal temporal and spatial control of expression of heme oxygenase-1 (HO-1) as the therapeutic transgene. We have reported that transgenic mice with cardiac-directed overexpression of HO-1 develop resistance to I/R-induced myocardial injury; furthermore, a single intramyocardial delivery of HO-1 gene by rAAV in rats, eight weeks in advance of I/R-induced myocardial injury, resulted in dramatic reduction in myocardial infarction, demonstrating that the combination of rAAV vector and HO-1 gene is an efficacious and feasible therapeutic strategy for myocardial protection. Accordingly, in this proposal we will (1) first document the impact of rAAV-mediated intramyocardial delivery of HO-1 on long-term survival following acute myocardial infarction induced by I/R injury and to determine the duration of expression and sustainability of the therapeutic effect of the transgene; (2) we will develop inducible, hypoxia and reoxygenation-sensitive expression of HO-1 as an endogenously regulated therapeutic approach for myocardial protection; (3) We will establish cardiomyocyte specific transgene expression of HO-1, and finally (4) we will develop a combined approach of cell-specific and inducible expression as an ideal strategy for transgene delivery with maximal tissue specificity and safety.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel strategy for Enhancing miRNA as a Therapeutic for Cardiac Regeneration
  • 批准号:
    9237608
  • 项目类别:
  • 资助金额:
    $39.75万
  • 财政年份:
    2016
  • 负责人:
    Victor J Dzau
  • 依托单位:
MYOCARDIAL PROTECTION OF HASF IN ACUTE MI
  • 批准号:
    8363208
  • 项目类别:
  • 资助金额:
    $0.31万
  • 财政年份:
    2011
  • 负责人:
    Victor J Dzau
  • 依托单位:
Sfrp2 as a Stem Cell Derived Paracrine Factor for Cardioprotection
  • 批准号:
    7145291
  • 项目类别:
  • 资助金额:
    $50.83万
  • 财政年份:
    2006
  • 负责人:
    Victor J Dzau
  • 依托单位:
Sfrp2 and Cardiac Progenitor Cells in Regenerative Response to Ischemic Injury
  • 批准号:
    8239268
  • 项目类别:
  • 资助金额:
    $43.8万
  • 财政年份:
    2006
  • 负责人:
    Victor J Dzau
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
去乙酰化酶SIRT1在前体mRNA可变剪切中的作用及其生理病理效应研究
  • 批准号:
    31970691
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2019
  • 负责人:
    张胜萍
  • 依托单位:
TM9SF4调控非小细胞肺癌细胞凋亡机制研究
  • 批准号:
    31900527
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2019
  • 负责人:
    孙磊
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位: